Short Interest in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Expands By 762.1%

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) saw a large growth in short interest in the month of May. As of May 15th, there was short interest totaling 1,457 shares, a growth of 762.1% from the April 30th total of 169 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily volume of 4,944 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Trading of Invesco Biotechnology & Genome ETF

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Raymond James Financial Inc. raised its stake in Invesco Biotechnology & Genome ETF by 1.8% during the 3rd quarter. Raymond James Financial Inc. now owns 8,078 shares of the company’s stock valued at $564,000 after purchasing an additional 141 shares during the period. NewEdge Advisors LLC raised its stake in Invesco Biotechnology & Genome ETF by 18.1% during the 4th quarter. NewEdge Advisors LLC now owns 1,043 shares of the company’s stock valued at $86,000 after purchasing an additional 160 shares during the period. Comerica Bank raised its stake in Invesco Biotechnology & Genome ETF by 86.2% during the 4th quarter. Comerica Bank now owns 378 shares of the company’s stock valued at $31,000 after purchasing an additional 175 shares during the period. PNC Financial Services Group Inc. raised its stake in Invesco Biotechnology & Genome ETF by 74.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 574 shares of the company’s stock valued at $40,000 after purchasing an additional 245 shares during the period. Finally, Newman Dignan & Sheerar Inc. raised its stake in Invesco Biotechnology & Genome ETF by 3.0% during the 4th quarter. Newman Dignan & Sheerar Inc. now owns 10,070 shares of the company’s stock valued at $827,000 after purchasing an additional 298 shares during the period.

Invesco Biotechnology & Genome ETF Trading Up 0.7%

Shares of PBE opened at $82.89 on Thursday. The business’s 50 day moving average is $80.06 and its 200 day moving average is $80.85. The company has a market capitalization of $257.79 million, a PE ratio of 20.44 and a beta of 0.71. Invesco Biotechnology & Genome ETF has a 12-month low of $62.25 and a 12-month high of $85.73.

About Invesco Biotechnology & Genome ETF

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.